Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Retained Earnings (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Retained Earnings for 7 consecutive years, with -$8000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 100.0% year-over-year to -$8000.0, compared with a TTM value of -$8000.0 through Dec 2025, up 100.0%, and an annual FY2025 reading of -$8000.0, up 100.0% over the prior year.
  • Retained Earnings was -$8000.0 for Q4 2025 at aTYR PHARMA, up from -$592.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$8000.0 in Q4 2025 and bottomed at -$592.2 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$285.5 million, with a median of -$403.5 million recorded in 2022.
  • The sharpest move saw Retained Earnings tumbled 718881.08% in 2024, then surged 100.0% in 2025.
  • Year by year, Retained Earnings stood at -$263000.0 in 2021, then plummeted by 158696.2% to -$417.6 million in 2022, then soared by 99.98% to -$74000.0 in 2023, then crashed by 718881.08% to -$532.0 million in 2024, then soared by 100.0% to -$8000.0 in 2025.
  • Business Quant data shows Retained Earnings for ATYR at -$8000.0 in Q4 2025, -$592.2 million in Q3 2025, and -$566.5 million in Q2 2025.